|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|US7122566||KING PHARMS||Metaxalone products, method of manufacture, and method of use|| |
(2 years from now)
Skelaxin is owned by King Pharms.
Skelaxin contains Metaxalone.
Skelaxin has a total of 1 drug patent out of which 0 drug patents have expired.
Skelaxin was authorised for market use on 30 August, 2002.
Skelaxin is available in tablet;oral dosage forms.
Skelaxin can be used as treatment of musculoskeletal conditions.
The generics of Skelaxin are possible to be released after 06 February, 2026.
Market Authorisation Date: 30 August, 2002
Treatment: Treatment of musculoskeletal conditions
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic